PE20051155A1 - Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos - Google Patents
Compuestos de imidazol para el tratamiento de trastornos neurodegenerativosInfo
- Publication number
- PE20051155A1 PE20051155A1 PE2005000313A PE2005000313A PE20051155A1 PE 20051155 A1 PE20051155 A1 PE 20051155A1 PE 2005000313 A PE2005000313 A PE 2005000313A PE 2005000313 A PE2005000313 A PE 2005000313A PE 20051155 A1 PE20051155 A1 PE 20051155A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- treatment
- alkenyl
- neurodegenerative disorders
- imidazole compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
REFERIDA A UN COMPUESTO DE FORMULA I DONDE A ESTA AUSENTE O ES SO2, ENTRE OTROS; R1 ES ALQUILO C1-C20, ALQUENILO C2-C20, ALQUENOXI C2-C20, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, CICLOALQUENILO C3-C8, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ENTRE OTROS; R4 ES H, ALQUILO C1-C6, HALO; R6 ES H, ALQUILO C1-C6, ALQUILENO C2-C6, HALO, ENTRE OTROS; R7 ES H, ALCOXI C1-C20, ALQUILO C1-C20, ENTRE OTROS. TAMBIEN REFERIDA A UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPUESTOS CUYOS PREFERIDOS SON: ESTER METILO DEL ACIDO 3-(4-{2-[2-(3,5-DIFLUOROFENIL)ACETILAMINO]PENTANOILAMINO}IMIDAZOL-1-IL)BUTIRICO; ESTER METILICO DEL ACIDO 3-{4-[2-(2-HIDROXI-3-METILBUTIRILAMINO)PENTANOILAMINO]IMIDAZOL-1-IL}-3-METILBUTIRICO; ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE Ab-PEPTIDOS Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS NEUROGENERATIVOS Y/O NEUROLOGICOS, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55562304P | 2004-03-23 | 2004-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20051155A1 true PE20051155A1 (es) | 2006-01-28 |
Family
ID=34961257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2005000313A PE20051155A1 (es) | 2004-03-23 | 2005-03-18 | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos |
Country Status (43)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2308441T3 (es) | 2004-03-23 | 2008-12-01 | Pfizer Products Incorporated | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos. |
| WO2007034326A2 (en) | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
| EA200801716A1 (ru) | 2006-01-18 | 2009-04-28 | Амген Инк. | Тиазольные соединения и их применение |
| DE102006048042A1 (de) * | 2006-10-11 | 2008-04-17 | Bayer Healthcare Ag | Acylaminoimidazole und Acylaminothiazole |
| ES2552764T3 (es) * | 2007-10-15 | 2015-12-02 | The Salk Institute For Biological Studies | Métodos para el tratamiento de varias enfermedades y afecciones, y compuestos útiles para los mismos |
| EP2253636A4 (en) * | 2008-01-23 | 2011-03-30 | Lead Chem Co Ltd | INHIBITOR OF NEURONAL CELL DEATH |
| EP2398771B1 (en) | 2009-02-18 | 2015-07-29 | Boehringer Ingelheim International GmbH | Heterocyclic compounds which modulate the cb2 receptor |
| CA2751534A1 (en) * | 2009-03-03 | 2010-09-10 | Pfizer Inc. | Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators |
| US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節する化合物 |
| EP2595959B1 (en) | 2010-07-22 | 2015-11-04 | Boehringer Ingelheim International GmbH | Sulfonyl compounds which modulate the cb2 receptor |
| RU2465273C2 (ru) * | 2010-08-31 | 2012-10-27 | Общество С Ограниченной Ответственностью "Биофарм-Меморейн" | ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| WO2013055386A2 (en) | 2011-10-03 | 2013-04-18 | The University Of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| WO2015092614A1 (en) | 2013-12-20 | 2015-06-25 | Pfizer Inc. | Activating notch alterations in breast cancer |
| TN2017000342A1 (en) | 2015-02-03 | 2019-01-16 | Pfizer | Novel cyclopropabenzofuranyl pyridopyrazinediones |
| US10294237B2 (en) | 2015-06-22 | 2019-05-21 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| CN107922386B (zh) | 2015-06-22 | 2021-04-02 | 大日本住友制药株式会社 | 1,4-二取代的咪唑衍生物 |
| JP6896701B2 (ja) | 2016-02-26 | 2021-06-30 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| EA201892075A1 (ru) | 2016-03-15 | 2019-04-30 | Оризон Дженомикс, С.А. | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| SG11202010579XA (en) | 2018-06-01 | 2020-12-30 | Novartis Ag | Binding molecules against bcma and uses thereof |
| WO2020043736A1 (en) * | 2018-08-27 | 2020-03-05 | Universiteit Maastricht | Selective presenilin-2 gamma-secretase inhibitors |
| CN114286828A (zh) | 2019-06-24 | 2022-04-05 | 诺华股份有限公司 | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 |
| US11884634B2 (en) | 2019-08-09 | 2024-01-30 | Pfizer Inc. | Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide |
| US10590087B1 (en) * | 2019-08-09 | 2020-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| AU2019461090A1 (en) * | 2019-08-09 | 2022-03-17 | Pfizer Inc. | Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof |
| WO2021066559A1 (en) * | 2019-10-02 | 2021-04-08 | Kainos Medicine, Inc. | N-(1h-imidazol-2-yl)benzamide compound and pharmaceutical composition comprising the same as active ingredient |
| CA3182887A1 (en) | 2020-05-13 | 2021-11-18 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
| TW202224703A (zh) | 2020-09-14 | 2022-07-01 | 美商輝瑞股份有限公司 | 治療癌症之方法、治療劑及用途 |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| WO2022253794A2 (en) | 2021-06-02 | 2022-12-08 | Cellestia Biotech Ag | Method for treating an autoimmune and inflammatory disease |
| IL311128A (en) | 2021-09-01 | 2024-04-01 | Springworks Therapeutics Inc | Synthesis of neurogestate |
| US11504354B1 (en) | 2021-09-08 | 2022-11-22 | SpringWorks Therapeutics Inc.. | Chlorinated tetralin compounds and pharmaceutical compositions |
| EP4429661A1 (en) | 2021-11-08 | 2024-09-18 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| CN118302412A (zh) * | 2021-11-23 | 2024-07-05 | 梯瓦制药国际有限责任公司 | Nirogacestat盐的固态形式 |
| EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| WO2023174390A1 (zh) * | 2022-03-17 | 2023-09-21 | 苏州科睿思制药有限公司 | 尼罗司他二氢溴酸盐的晶型及其制备方法和用途 |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11872211B2 (en) | 2022-05-20 | 2024-01-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US50314A (en) * | 1865-10-03 | Improvement in telegraph-cables | ||
| US4512A (en) * | 1846-05-09 | Smut-machine | ||
| DE1236426B (de) * | 1960-08-25 | 1967-03-09 | Dolomitwerke Gmbh | Verfahren zur Wasseraufbereitung |
| US5401851A (en) | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| JPH07101958A (ja) | 1992-10-16 | 1995-04-18 | Takeda Chem Ind Ltd | セフェム化合物、その製造法および抗菌組成物 |
| DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| US5760246A (en) | 1996-12-17 | 1998-06-02 | Biller; Scott A. | Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method |
| US6329342B1 (en) * | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
| ZA987383B (en) | 1997-08-19 | 2000-02-17 | Lilly Co Eli | Treatment of congestive heart failure with growth hormone secretagogues. |
| ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
| US6639076B1 (en) * | 1998-08-18 | 2003-10-28 | Eli Lilly And Company | Growth hormone secretagogues |
| US6828331B1 (en) * | 1999-02-19 | 2004-12-07 | Eli Lilly And Company | Growth hormone secretagogues |
| CO5160260A1 (es) * | 1999-02-19 | 2002-05-30 | Lilly Co Eli | Secretagogos de la hormona del crecimiento derivados de imi- dazol 1,4- substituido |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| DE10019755A1 (de) | 2000-04-20 | 2001-11-08 | Bayer Ag | Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten |
| CA2410597A1 (en) | 2000-05-30 | 2001-12-06 | Merck & Co., Inc. | Melanocortin receptor agonists |
| GT200100147A (es) * | 2000-07-31 | 2002-06-25 | Derivados de imidazol | |
| JP2002059707A (ja) * | 2000-08-23 | 2002-02-26 | Bridgestone Corp | 空気入りタイヤ及び空気入りタイヤの製造方法 |
| JP2004513935A (ja) * | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | グルカゴンアンタゴニスト／逆アゴニスト |
| EP1458382A1 (en) | 2001-12-21 | 2004-09-22 | Novo Nordisk A/S | Amide derivatives as gk activators |
| TW200301698A (en) | 2001-12-21 | 2003-07-16 | Bristol Myers Squibb Co | Acridone inhibitors of IMPDH enzyme |
| PL374017A1 (en) | 2002-06-05 | 2005-09-19 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
| MXPA05003432A (es) * | 2002-10-09 | 2005-07-05 | Pfizer Prod Inc | Compuestos pirazoles para el tratamiento de trastornos neurodegenerativos. |
| AU2003265068A1 (en) * | 2002-10-09 | 2004-05-04 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| JP2006182648A (ja) * | 2003-04-08 | 2006-07-13 | Dai Ichi Seiyaku Co Ltd | ７員複素環誘導体 |
| CA2524511A1 (en) * | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| BRPI0413245A (pt) * | 2003-08-01 | 2006-10-03 | Pfizer Prod Inc | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos |
| BRPI0413349A (pt) * | 2003-08-06 | 2006-10-10 | Pfizer Prod Inc | compostos de oxazol para o tratamento de doenças neurodegenerativas |
| CA2534532A1 (en) * | 2003-08-21 | 2005-03-10 | Pfizer Products, Inc. | Compounds for the treatment of neurodegenerative disorders |
| US7348968B2 (en) * | 2003-12-02 | 2008-03-25 | Sony Corporation | Wireless force feedback input device |
| GB0329275D0 (en) | 2003-12-18 | 2004-01-21 | Merck Sharp & Dohme | Therapeutic treatment |
| ES2308441T3 (es) | 2004-03-23 | 2008-12-01 | Pfizer Products Incorporated | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos. |
| US7309709B2 (en) * | 2004-04-01 | 2007-12-18 | Pfizer Inc. | Thiazole sulfonamide compounds for the treatment of neurodegenerative disorders |
| US20050222227A1 (en) * | 2004-04-01 | 2005-10-06 | Pfizer Inc | Oxazole-amine compounds for the treatment of neurodegenerative disorders |
| US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7163942B2 (en) * | 2004-04-01 | 2007-01-16 | Pfizer Inc. | Sulfonamide compounds for the treatment of neurodegenerative disorders |
| US7384968B2 (en) * | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
| WO2007034326A2 (en) * | 2005-09-22 | 2007-03-29 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
-
2005
- 2005-03-11 ES ES05708746T patent/ES2308441T3/es active Active
- 2005-03-11 EP EP05708746A patent/EP1730119B1/en active Active
- 2005-03-11 UA UAA200610159A patent/UA83899C2/uk unknown
- 2005-03-11 AU AU2005225635A patent/AU2005225635B2/en active Active
- 2005-03-11 SI SI200530339T patent/SI1730119T1/sl unknown
- 2005-03-11 CN CN2005800093217A patent/CN1934091B/zh active Active
- 2005-03-11 AP AP2006003727A patent/AP2379A/xx active
- 2005-03-11 GE GEAP20059630A patent/GEP20084420B/en unknown
- 2005-03-11 CA CA002560580A patent/CA2560580C/en active Active
- 2005-03-11 JP JP2007504496A patent/JP4054845B2/ja active Active
- 2005-03-11 US US11/078,898 patent/US7342118B2/en active Active
- 2005-03-11 DK DK05708746T patent/DK1730119T3/da active
- 2005-03-11 NZ NZ549331A patent/NZ549331A/en not_active IP Right Cessation
- 2005-03-11 AT AT05708746T patent/ATE399155T1/de active
- 2005-03-11 WO PCT/IB2005/000659 patent/WO2005092864A1/en active Application Filing
- 2005-03-11 PL PL05708746T patent/PL1730119T3/pl unknown
- 2005-03-11 DE DE602005007717T patent/DE602005007717D1/de active Active
- 2005-03-11 KR KR1020067019625A patent/KR100814599B1/ko active IP Right Grant
- 2005-03-11 BR BRPI0509069A patent/BRPI0509069B8/pt active IP Right Grant
- 2005-03-11 PT PT05708746T patent/PT1730119E/pt unknown
- 2005-03-11 RS RSP-2008/0351A patent/RS50595B/sr unknown
- 2005-03-11 EA EA200601494A patent/EA011689B1/ru not_active IP Right Cessation
- 2005-03-18 PE PE2005000313A patent/PE20051155A1/es not_active Application Discontinuation
- 2005-03-18 HN HN2005000115A patent/HN2005000115A/es unknown
- 2005-03-18 SV SV2005002055A patent/SV2006002055A/es unknown
- 2005-03-18 TW TW094108466A patent/TWI372146B/zh active
- 2005-03-21 GT GT200500060A patent/GT200500060A/es unknown
- 2005-03-21 DO DO2005000040A patent/DOP2005000040A/es unknown
- 2005-03-22 UY UY28817A patent/UY28817A1/es not_active Application Discontinuation
- 2005-03-22 NL NL1028598A patent/NL1028598C2/nl active Search and Examination
- 2005-03-22 AR ARP050101116A patent/AR049875A1/es not_active Application Discontinuation
- 2005-03-23 PA PA20058627201A patent/PA8627201A1/es unknown
-
2006
- 2006-08-21 IL IL177594A patent/IL177594A0/en active IP Right Grant
- 2006-08-21 ZA ZA2006/06957A patent/ZA200606957B/en unknown
- 2006-09-21 CR CR8644A patent/CR8644A/es unknown
- 2006-09-22 MA MA29336A patent/MA28481B1/fr unknown
- 2006-09-22 EC EC2006006879A patent/ECSP066879A/es unknown
- 2006-09-22 TN TNP2006000300A patent/TNSN06300A1/fr unknown
- 2006-10-09 IS IS8550A patent/IS8550A/is unknown
- 2006-10-18 NO NO20064726A patent/NO338263B1/no unknown
-
2007
- 2007-05-29 HK HK07105652.1A patent/HK1099756A1/xx unknown
- 2007-06-13 JP JP2007156459A patent/JP2007291123A/ja active Pending
-
2008
- 2008-01-09 US US11/971,272 patent/US7795447B2/en active Active
- 2008-07-29 HR HR20080375T patent/HRP20080375T3/xx unknown
- 2008-09-17 CY CY20081101001T patent/CY1108347T1/el unknown
-
2010
- 2010-03-12 US US12/723,204 patent/US7951958B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20051155A1 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| PE20051146A1 (es) | Compuestos heterociclicos anticitocina | |
| PE20080319A1 (es) | Dihidrotienopirimidinas como agentes inhibidores de pde-4 | |
| PE20030856A1 (es) | Esteres hidroxamato del acido n-(4-fenilsustituido)-antranilico | |
| MY142807A (en) | Benzimidazole derivative and use thereof. | |
| PE20060215A1 (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| PE20120355A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| IS7170A (is) | Bensóþíasepín og bensóþíadíasepínafleiður með tálmavirkni gegn dausgarnargallsýruflutningi (ileal bile acid transport, IBAT) til að meðhöndla fitudreyra | |
| PE20040762A1 (es) | Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer | |
| PE20081359A1 (es) | Compuestos de azabenzotiofenil como inhibidores de la quinasa mek | |
| PE20081135A1 (es) | Derivados que contienen sulfamoilo y sus usos | |
| PE20100561A1 (es) | Derivados de piridazina como agentes inhibidores de esteaorilcoa desaturasa | |
| PE20081704A1 (es) | Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa | |
| PE20050232A1 (es) | Metodo y composiciones para tratar la artritis reumatoide | |
| FI942381A0 (fi) | Aryylisubstituoituja heterosyklisiä yhdisteitä | |
| PE20020870A1 (es) | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas | |
| PE20081545A1 (es) | Derivados de sulfonamida como inhibidores de acido graso sintasas | |
| PE20060748A1 (es) | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 | |
| DE3850203D1 (de) | Benzimidazolin-2-oxo-1-carboxylsäure-Derivate, verwendbar als Antagonisten von 5-HT-Rezeptoren. | |
| PE20050131A1 (es) | Derivados de benzoimidazol como agentes antiproliferativos | |
| PE20060315A1 (es) | Compuestos de tiazol como moduladores de ppar | |
| PE20040898A1 (es) | Nuevos compuestos derivados de pirimidina | |
| PE20061451A1 (es) | Compuestos derivados de diarilsulfona sulfonamidas | |
| WO2005092895A3 (en) | Alpha aryl or heteroaryl methyl beta piperidino propanoic acid compounds as orl1-receptor antagonists | |
| PE20011008A1 (es) | Derivados de pirimidina como inhibidores de ciclooxigenasa 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |